Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics' stock price has experienced significant volatility over the past six months. The stock has seen a significant increase, with a 6-month performance of +152.67% as of January 2026, but decreased by 38.86% in the past month. Key events include progress in the Phase 3 NEAT clinical trial for Ataxia-Telangiectasia, positive analyst ratings and price targets from firms like Citizens and JMP Securities, participation in investor events, publication of safety and pharmacokinetic data, and financial and corporate updates such as an amendment to its credit facility.

As a pre-commercial biopharmaceutical company, Quince Therapeutics does not exhibit traditional demand seasonality. However, an analysis of its stock price over the past five years suggests a potential seasonal pattern, with a "Buy Date" of December 11 and a "Sell Date" of March 22, resulting in a geometric average return of 16.57% above the S&P 500 Total Return Index. This seasonal timeframe for QNCX correlates poorly with the broader Healthcare sector's seasonal strength, which typically runs from April 25 to December 4.

Quince Therapeutics, Inc. is a late-stage biopharmaceutical company focused on acquiring, developing, and commercializing therapeutics for rare diseases, operating in the Biotechnology industry. The company utilizes its AIDE technology platform to encapsulate drugs into a patient's own red blood cells. Its lead asset, EryDex, is being developed for Ataxia-Telangiectasia, and it has a Phase 2 clinical trial planned for Duchenne Muscular Dystrophy in 2025. The company changed its name from Cortexyme, Inc. in August 2022.

Quince Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company's operations are focused on clinical development and research.

Quince Therapeutics' brand reputation is influenced by its clinical trial progress and positive analyst sentiment. The company has received positive ratings from analysts and has seen successful enrollment and positive reviews for its Phase 3 NEAT clinical trial. Publication of positive safety and pharmacokinetic data and participation in investor events also contribute positively to its reputation. There is no readily available information suggesting specific events that have negatively affected Quince Therapeutics' brand reputation in the past year.

Quince Therapeutics, Inc. has a diverse ownership structure. Institutional shareholders own between 21.18% and 30.75% of the stock, insiders hold 73.99%, and retail investors own 4.83%. Major institutional owners include Nantahala Capital Management, LLC, and Vanguard Group Inc. The largest individual shareholder is Epiq Capital Group LLC, owning 40.86% of the company.